广告
加载中

中签即被套?上市1个月股价腰斩 同仁堂医养的中医生意不好做

于莹 2026-08-19 08:45
于莹 2026/08/19 08:45

邦小白快读

EN
全文速览

总:本文核心讲述了背靠三百年同仁堂老字号的同仁堂医养上市后股价腰斩的事件,梳理了事件前因后果,给普通读者和投资者提供了清晰的参考干货。

1. 核心事件梳理:同仁堂医养是同仁堂集团旗下第四家上市公司,也是国内规模最大的非公立中医院集团,上市前三次递表失效,曾因认购不足紧急叫停上市,发行价从最高8.3港元砍至5.5港元,募资缩水超四成,上市仅一个月股价较发行价腰斩,Pre-IPO、基石、打新三类投资者全部被套。

2. 核心风险提示:该公司自身基本面不佳,三年营收增速不足2%,增长靠并购,利润靠出售资产,发行市盈率超80倍远高于同行;行业本身难以规模化扩张,核心品牌为集团授权,存在品牌管控风险,普通投资者打新需要警惕这类仅靠品牌光环支撑的高估值标的。

总:本文通过同仁堂医养IPO遇冷的案例,给中医健康领域的品牌商带来了多维度的经营启示,干货如下。

1. 品牌管理启示:同仁堂集团的品牌授权乱象已经透支了品牌信誉,授权到期三年仍有大量贴牌产品在市场流通,品质管控缺位,说明采用品牌授权模式的品牌商,必须建立全周期的授权管控机制,及时清理到期违规授权,严格把控贴牌产品品质,避免百年品牌信用被透支。

2. 业务布局启示:同仁堂医养业务高度集中在中医医疗,收入近七成来自北京、浙江两地,多元化和全国化布局未达预期,说明品牌商需要避免业务结构过度集中,提前布局多元业务分散风险,全国化扩张要适配中医行业的个性化特性,不能盲目铺摊子。

3. 资本运作启示:自身盈利能力不佳却依靠品牌光环定高市盈率,最终不被市场认可,说明品牌商IPO定价要匹配自身业绩和行业平均水平,不能过度透支品牌价值。

总:本文分析了非公立中医医疗服务行业的现状与同仁堂医养的问题,给中医健康领域的卖家梳理了机会与风险,干货如下。

1. 行业格局梳理:中医医疗服务行业极度分散,前两大龙头企业合计市占率不到1%,理论上整合空间极大,但行业天生存在模式制约:中医核心是一人一方的个性化诊疗,高度依赖名医资源,名医培养周期长、流动性强,很难像西医一样标准化复制规模化扩张,头部企业也难以形成规模壁垒。

2. 核心风险提示:如果依托老字号品牌开展经营,需要格外注意品牌授权风险,若核心品牌不属于自身,授权条款变动、集团品牌策略调整都会直接动摇经营根基;市场不会仅为品牌光环买单,卖家需要打磨自身的内生盈利能力,不能只靠品牌背书。

3. 机会提示:消费者对正规优质的中医医疗健康服务需求持续增长,行业整体规模大,若能解决名医资源培养、标准化复制的痛点,就能享受行业整合的红利。

总:本文对中医医疗及中医健康产品生产加工工厂,梳理了行业需求与商业机会,干货如下。

1. 产品端机会:当前中医健康产品领域存在大量老字号授权贴牌的乱象,产品品质参差不齐,消费者对合规、高品质的正宗中医健康产品有旺盛的未满足需求,工厂若能和正规品牌方合作,严格把控产品品质,就能获得稳定的市场机会。

2. B端商业机会:中医医疗服务行业未来整合是大趋势,头部连锁中医机构扩张过程中,会产生对中药饮片、诊疗器材、健康周边产品的规模化需求,工厂可以提前对接头部机构,拓展稳定的B端业务。

3. 经营风险提示:工厂承接贴牌代工订单时,一定要核查品牌授权的合规性,避免卷入违规授权的乱象,损害自身的市场声誉;针对中医一人一方的个性化需求,可以布局柔性化生产能力,适配行业特性,提升自身竞争力。

4. 数字化启示:中医个性化诊疗对柔性供应链需求高,工厂可以推进数字化生产改造,适配小批量多品类的生产需求,抓住行业特性带来的机会。

总:本文拆解了中医医疗服务行业的核心痛点与发展趋势,给服务中医行业的各类服务商指明了业务方向,干货如下。

1. 行业核心痛点梳理:当前中医行业的核心痛点一是难以标准化复制,规模化扩张受名医资源稀缺的制约;二是老字号品牌授权管理混乱,品牌方缺乏有效的管控手段;三是多数头部企业内生增长不足,增长靠并购,缺乏持续增长能力。

2. 业务机会梳理:针对中医标准化的痛点,服务商可以开发适配中医诊疗的数字化辅助工具,帮助机构整理名医诊疗经验,降低机构对单个名医的依赖,提升诊疗标准化程度;针对品牌管控痛点,可开发全周期授权管理系统,帮助品牌方实时监控授权产品流通,及时清理违规到期授权。

3. 行业趋势判断:中医医疗服务行业整合是长期趋势,未来头部机构扩张过程中,会产生大量人才培养、供应链管理、数字化转型的服务需求,市场空间广阔。

总:本文给中医健康领域相关的平台商,梳理了运营管理优化和风险规避的方向,干货如下。

1. 电商平台运营启示:同仁堂过期授权的贴牌产品仍能在电商平台正常销售,说明平台对第三方商品的品牌授权合规性审核存在漏洞,平台需要完善入驻审核机制,定期排查清理违规过期授权的商品,避免损害消费者权益,影响平台自身声誉。

2. 证券交易平台启示:同仁堂医养自身基本面不佳,却能以远超行业平均的市盈率IPO,上市后股价腰斩套牢大量投资者,说明平台在审核IPO项目时,需要更关注标的的内生增长能力,引导合理定价,保护二级市场投资者利益。

3. 招商与风险规避:平台引入中医健康类商家或项目时,要重点核查品牌权属关系,关注标的的真实盈利能力,警惕仅靠品牌光环、业绩靠并购和资产处置支撑的标的,提前规避后续的经营和市场风险。

总:本文以同仁堂医养IPO遇冷为典型案例,揭示了中医医疗服务产业和老字号资产证券化的新问题,给产业研究提供了丰富的样本,干货如下。

1. 产业特性新发现:虽然中医医疗服务市场规模大,行业分散整合空间足,但受制于中医一人一方的个性化诊疗本质,行业高度依赖名医资源,天生难以标准化复制和规模化扩张,现有连锁扩张模式存在明显瓶颈,头部企业很难建立规模壁垒和定价权,这是此前研究中没有被充分重视的行业特性。

2. 老字号开发的新问题:老字号品牌多品牌授权贴牌的模式,虽然能短期获得收益,但普遍存在管控漏洞,品牌价值被持续透支,同仁堂医养核心品牌靠授权、自身无核心无形资产的模式,也暴露了老字号分拆上市过程中的架构问题,值得深入研究。

3. 资本运作的新启示:部分背靠老字号的IPO标的,依靠品牌光环支撑高估值,自身内生增长不足,这种模式已经不被市场认可,为研究老字号资产证券化提供了新案例,也提示政策层面需要加强对这类标的的信息披露要求和估值引导。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

This article centers on Tongrentang Yiyang, the listed healthcare arm of 300-year-old heritage Chinese medicine brand Tongrentang, whose share price has halved since its IPO. It unpacks the full context of the event to provide clear, actionable insights for general readers and investors.

1. Key event recap: Tongrentang Yiyang is the fourth listed company under the Tongrentang Group and China's largest non-public Chinese hospital group. Before going public, three of its prospectuses expired, it aborted an IPO due to under-subscription, and it cut its offering price from a planned high of HK$8.3 to HK$5.5, reducing total fundraising by more than 40%. Just one month after listing, its share price has halved from the issue price, leaving all three groups of pre-IPO investors, cornerstone investors and retail IPO subscribers holding underwater positions.

2. Key risk warnings: The company has weak core fundamentals, with three-year revenue growth of less than 2%, expansion driven entirely by acquisitions and profit growth supported by asset sales. It priced its IPO at a P/E ratio of more than 80x, far higher than industry peers. The Chinese medicine hospital industry inherently struggles with large-scale expansion, and Tongrentang Yiyang's core brand is licensed from the parent group, creating material brand governance risks. Retail investors are warned to be cautious of high-valuation IPO candidates that rely solely on the glow of a famous brand name.

This article draws multi-dimensional business insights for brand owners in the traditional Chinese medicine (TCM) and wellness industry through the case of Tongrentang Yiyang's cold IPO reception.

1. Brand management takeaway: The widespread poorly regulated brand licensing practices at Tongrentang have eroded the brand's long-term reputation. Large volumes of unlicensed private-label products remain on the market years after licensing agreements expired, due to lax quality oversight. This shows that brand owners using a licensing model must build full-cycle license management mechanisms, promptly clear out expired and non-compliant licensed products, and strictly enforce quality controls for private-label goods to avoid draining a century-old brand's credit.

2. Business layout takeaway: Tongrentang Yiyang's business is heavily concentrated in TCM medical services, with nearly 70% of revenue coming from just two regions: Beijing and Zhejiang. Its diversification and national expansion efforts have underperformed. This shows brands should avoid over-concentrated business structures, proactively build diversified businesses to spread risk, and align national expansion with the inherently personalized nature of the TCM industry, rather than pursuing blind aggressive expansion.

3. Capital strategy takeaway: When a company with weak core profitability chases a high valuation purely based on its brand heritage, it will ultimately be rejected by the market. This makes clear that IPO pricing must align with a company's actual performance and industry averages, and brands should not overleverage their existing brand value.

This article analyzes the current state of the non-public TCM medical services industry and the specific problems facing Tongrentang Yiyang, to outline key opportunities and risks for sellers in the TCM and wellness space.

1. Industry landscape overview: The TCM medical services industry is extremely fragmented, with the top two players holding a combined market share of less than 1%. While there is theoretically huge room for industry consolidation, the sector faces inherent structural constraints: TCM's core value lies in personalized, one-patient-one-prescription treatment that relies heavily on experienced TCM practitioners. These practitioners have long training cycles and high mobility, making standardized, large-scale expansion far harder than in Western medicine, even for leading firms that struggle to build scalable competitive moats.

2. Key risk warnings: Sellers operating under a heritage brand license must pay special attention to licensing risks. If you do not own the core brand yourself, changes to licensing terms or adjustments to the parent group's brand strategy can directly undermine your business foundation. The market will not reward a brand name alone; sellers must build their own organic profitability instead of relying purely on a third-party brand endorsement.

3. Opportunity outlook: Consumer demand for legitimate, high-quality TCM medical and wellness services continues to grow, and the industry already has a large overall size. Businesses that can solve the core pain points of cultivating practitioner talent and enabling standardized, replicable services will be able to capture significant consolidation-driven growth.

This article outlines industry demand and business opportunities for manufacturers of TCM medical products and TCM wellness goods.

1. Product-side opportunities: The TCM wellness product space is currently rife with unregulated licensing and private-label production from heritage brands, leading to wildly inconsistent product quality. There is strong unmet consumer demand for compliant, high-quality authentic TCM wellness products. Manufacturers that partner with legitimate brand owners and enforce strict quality controls can secure stable market opportunities.

2. B2B business opportunities: Industry consolidation is the long-term trend for TCM medical services. As leading chain TCM institutions expand, they will create large-scale, steady demand for TCM herbal slices, medical equipment and wellness-related products. Manufacturers can proactively partner with leading institutional clients to build stable B2B business lines.

3. Operational risk warnings: When accepting private-label OEM orders, manufacturers must verify the compliance of brand licensing authorizations to avoid being drawn into non-compliant licensing practices that damage their own market reputation. To accommodate the personalized, one-prescription-per-patient nature of TCM, manufacturers can build flexible production capabilities that align with industry characteristics to boost competitiveness.

4. Digital transformation takeaway: TCM's personalized treatment model creates strong demand for flexible supply chains. Manufacturers can pursue digital production upgrades to meet the needs of small-batch, multi-SKU production, and capture opportunities created by the industry's unique characteristics.

This article breaks down the core pain points and development trends of the TCM medical services industry, and outlines clear business directions for service providers serving the TCM sector.

1. Core industry pain points: Three core bottlenecks face the sector today. First, the industry cannot easily standardize and scale operations, due to the persistent shortage of experienced TCM practitioners. Second, legacy brand licensing practices are poorly managed, and brand owners lack effective governance tools. Third, most leading firms lack strong organic growth, relying on acquisitions to expand rather than building sustainable internal growth.

2. Key business opportunities: For the standardization pain point, service providers can develop digital assisted diagnostic tools tailored for TCM practice, to help institutions codify the clinical experience of top practitioners, reduce reliance on individual highly skilled doctors, and improve the standardization of care. For the brand governance pain point, providers can build full-cycle license management systems to help brand owners monitor the circulation of licensed products in real time and promptly remove non-compliant and expired licensed goods.

3. Industry trend outlook: Consolidation is a long-term trend for the TCM medical services industry. As leading institutions expand in the coming years, they will generate widespread demand for services including talent development, supply chain management and digital transformation, creating significant market opportunities.

This article outlines directions for operational optimization and risk mitigation for platform operators in the TCM and wellness sector.

1. E-commerce platform takeaway: Expired-license private-label Tongrentang products remain available for sale on e-commerce platforms, exposing gaps in platforms' review of brand authorization compliance for third-party goods. Platforms need to improve their onboarding review mechanisms and conduct regular audits to remove non-compliant products with expired authorizations, to avoid harming consumers and damaging the platform's own reputation.

2. Securities exchange takeaway: Tongrentang Yiyang had weak core fundamentals but was able to price its IPO at a P/E ratio far above the industry average, before its share price halved post-listing and left large numbers of investors with losses. This shows exchanges need to place greater focus on the organic growth capacity of IPO candidates, enforce guidance for reasonable pricing, and better protect the interests of secondary market investors.

3. Business onboarding and risk mitigation: When onboarding TCM and wellness merchants or investment projects, platforms need to prioritize verifying brand ownership, assess the target's actual profitability, and be wary of candidates that rely solely on brand prestige and deliver growth only through acquisitions and asset sales, to proactively avoid future operational and market risks.

This paper uses Tongrentang Yiyang's underperforming IPO as a case study to reveal new issues in the TCM medical services industry and the securitization of heritage Chinese brand assets, providing a rich new sample for industrial research.

1. New findings on industry characteristics: While the TCM medical services market has large scale and significant room for fragmented industry consolidation, its core nature of personalized one-patient-one-prescription care leaves the sector heavily reliant on experienced practitioners, and inherently difficult to standardize and scale. Existing chain expansion models face clear bottlenecks, and leading firms struggle to build scale moats or pricing power. This key industry characteristic has not received sufficient attention in prior research.

2. New issues in heritage brand development: While multi-brand licensing and private-label production by heritage brands generates short-term revenue, it generally suffers from governance gaps that steadily erode brand value. The model of Tongrentang Yiyang, which relies on licensing for its core brand and owns no key core intangible assets itself, also exposes structural issues in the spin-off listing process for heritage brands, which deserves further in-depth research.

3. New insights for capital strategy: Some IPO candidates backed by heritage brands pursue high valuations purely based on brand reputation while lacking organic internal growth, and this model is no longer accepted by the market. This provides a new case for research on the securitization of heritage brand assets, and highlights the need for policymakers to strengthen disclosure requirements and valuation guidance for this category of issuer.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

今年7月,港交所迎来了一位“含着金汤匙”的新成员——同仁堂医养。

作为同仁堂集团旗下第四家上市公司,其背靠三百余年老字号品牌。按2025年总门诊人次及住院人次计,同仁堂医养是中国非公立中医院医疗服务行业中最大的中医院集团,市场份额为1.5%。

然而,资本市场却反应冷淡。

上市首日(7月7日),同仁堂医养以4.76港元/股低开,盘中短暂触及4.79港元/股的高点后便一路震荡下行,当日最终收报3.35港元/股,单日暴跌39.09%。

此后的一个多月里,跌势仍在延续。截至8月18日,股价收于2.665港元/股,较5.5港元/股的发行价已腰斩。

这并非同仁堂医养第一次在资本市场碰壁。从2024年6月首次递表算起,公司在港交所门口苦等了整整两年。在这期间,公司不仅经历了招股书三次失效,还曾因认购数不够上市前夕紧急叫停,推迟上市时间。

重启招股后,公司发行价从最高的8.3港元/股一路砍至5.5港元/股,募资规模缩水超过四成。

而上市之后,公司股价又出现腰斩。这意味着,中签的投资者几乎从敲钟第一天起就被套牢。

一家背靠三百年老字号、行业规模第一的公司,为何在资本市场屡屡碰壁?

01 增长靠“买”、利润靠“卖”,发行市盈率却超80倍

同仁堂医养成立于2015年,是同仁堂集团旗下战略性聚焦中医医疗服务的附属公司。公司以“医”与“养”结合为定位,提供现代化的中医诊疗服务,涵盖药物治疗与非药物疗法。

其实,公司的营收规模不算小,但增长几乎停滞。2023年至2025年,同仁堂医养营业收入分别为11.53亿元、11.75亿元、11.71亿元,三年累计增速不足2%,2025年甚至同比微降0.3%。

营收原地踏步的同时,业务结构也高度集中。2025年,中医医疗服务贡献约85%的收入,是绝对核心支柱;管理服务和健康产品销售分别仅占1.4%和12.8%,多元化业务尚未形成规模支撑。

而中医医疗服务的经营区域也相当集中,北京、浙江两地合计贡献近七成收入,所谓的“全国化布局”暂未体现明显成效。

值得一提的是,如果进一步拆分会发现,公司的收入增长来自外延并购。

2023年-2025年,来自收购医疗机构的并表收入分别为5.09亿元、5.98亿元、5.98亿元,占总营收的44%-51%。也就是说,公司约一半的收入是靠“买进来的”。

利润端的故事更加耐人寻味。2023年至2025年,同仁堂医养净利润分别为4263.4万元、4619.7万元、3375万元。

2024年,净利润实现了8.4%的同比增幅,实则靠的是出售石家庄同仁堂中医医院获得的一次性资产处置收益约1710万元。2025年失去这笔处置款后,净利润同比下滑26.9%。

收入增长靠并购资产、利润增长靠甩卖资产,但仍将同仁堂医养送上了资本市场。

「子弹财经」了解到,2024年6月至2025年6月,公司三度递表港交所,均未能推进至挂牌。直到2026年1月第四次递表后,才得以再进一步。

2026年3月,公司首次启动招股,发行区间定在7.30/股至8.30港元/股,按最高上限价计算,募资近9亿港元。然而,香港公开发售孖展认购倍数仅4.85倍,热度远不及预期,上市前三天紧急叫停,推迟上市时间。

时隔三个月,公司于6月重启IPO,大幅下调发行价,最终以5.50港元/股定价。即便如此,对应首发市盈率仍超过80倍。

同为港股民营中医服务标的,固生堂市盈率仅约15倍,而固生堂2025年实现营收32.49亿元、净利润3.53亿元,无论是规模还是盈利能力都远超同仁堂医养。

即便在同仁堂体系内部,兄弟公司同仁堂科技PE约9倍,同仁堂国药PE约13倍。差距可谓之大。

上市之后,同仁堂医养的股价快速下跌。于8月18日收盘,同仁堂医养报收2.665港元/股,较发行价下滑51.5%。

02 行业分散,“同仁堂”品牌来自授权

中医医疗服务行业极度分散,头部企业市场份额极低,未来整合空间巨大,理论上意味着更高的成长天花板。

按2025年总门诊人次及住院人次计,同仁堂医养已是中国非公立中医院医疗服务行业中最大的中医院集团,市场份额为1.5%;按2025年中医医疗服务总收入计,则以0.2%的市场份额在非公立中医院医疗服务行业中排名第二,其市场规模占同年中国中医医疗服务行业市场总规模的54.9%。

要知道,行业第一的固生堂市场份额也只有0.3%。两家已经上市的龙头公司的市占率总和,还不到整个市场的1%。

一般来说,行业越分散,整合空间越大,谁率先跑出来,谁就能享受行业集中的红利,就像连锁餐饮、民营眼科、口腔医疗等赛道,都经历了从“千军万马”走向“头部集中”的过程。

但问题在于,历史悠久的中医医疗,为何尚未走出这条路?

原因要从中医的诊疗本质说起。不同于西医建立在标准化诊断流程、统一用药指南和精密设备之上的服务体系,中医的核心是“一人一方”——同一种疾病,因患者体质、季节气候、地域水土不同,处方可能截然不同。

这种高度个性化的诊疗方式,意味着医疗服务难以像工业品一样标准化复制。国金证券研报指出,中医自古以家传、师承为主,形成了经方派、温病派、伤寒派等不同学术流派,诊疗方法和用药习惯差异显著。

流派之外,还有气候、药材资源和疾病谱系的地域差异,催生了“岭南医学”“海派中医”等地方性流派,进一步加剧了行业的分散性。

这也就意味着,这个行业天生更倾向于个体化经营,而非公司化、连锁化。西医体系下,一台手术、一套检验的流程容易复制,医生只是执行标准方案的“操作者”;中医体系下,每个病人的诊治都不相同,医生本身就是“生产工具”。

2023年至2025年,5名医师每年为同仁堂医养贡献9%左右的收入。其中,单名医师的贡献金额在2000万元左右,可见知名医师“吸金”之强劲。

这意味着,连锁中医院的核心资产不仅是门店、设备,更重要的是坐诊的医生,而名医资源稀缺、培养周期长、流动性强,天然构成了规模化扩张的天花板,头部企业既缺乏定价权,也难形成规模壁垒,任何一家想要“一统江湖”,都面临模式制约。

除了行业分散,公司在品牌使用上还存在隐患。

同仁堂医养最核心的竞争壁垒,是“同仁堂”三个字所代表的品牌效应。但这三个字,并不属于公司。

招股书显示,“同仁堂”商标所有权握在同仁堂集团手中,同仁堂医养使用该品牌,是基于集团授权。这意味着,公司最核心的无形资产,并不完全受控于自身,授权条款一旦变更,或集团层面对品牌策略有所调整,公司赖以立身的品牌根基就会松动。

“同仁堂”品牌的授权乱象,已有前车之鉴。

在2025年底的“南极磷虾油”事件中,一款标称“北京同仁堂99%高纯”的产品宣称磷脂含量43%,上海市消保委实测结果为0。该产品由安徽哈博药业代工,经北京同仁堂(四川)健康药业(以下简称:四川健康)贴牌销售。

同仁堂集团事后声称,对四川健康的品牌授权早在2021年就已到期。然而授权已到期,标称“同仁堂”的产品却仍在电商平台上销售,从磷虾油、鱼油到足浴包、养生茶,产品五花八门,被外界戏称为“同仁堂宇宙”。

这一事件暴露出两个层面的问题。其一,“同仁堂”品牌在被广泛授权、贴牌使用的过程中,品质管控已经出现明显漏洞,消费者冲着“百年老字号”的信誉买单,买到的却是代工厂的贴牌产品,品牌信用正在被透支。其二,集团层面对授权的管控力度存疑,授权到期三年仍未清理,说明品牌管理机制本身存在疏漏。

站在同仁堂的肩膀上,同仁堂医养得以登陆港交所。但在“同仁堂”这块招牌之外,自身的竞争壁垒又在哪里?

03 从Pre-IPO到打新,投资者纷纷被套

同仁堂医养股价腰斩背后,不同阶段入场的投资者,几乎无一例外地陷入浮亏。

最早被套的,是上市前入股的投资者。2024年3月,同仁堂养老基金、同仁堂医养基金、同清基金、同康基金、朱智彪、潘松琴等6名首次公开发售前投资者对公司进行增资,上述6名Pre-IPO投资者合计出资3.66亿元认购公司5720.85万元注册资本,(成本约4.26亿港元),对应入股成本为6.39元/股,折合约7.43港元/股。

Pre-IPO轮是企业在上市前最后一轮私募融资,投资者以接受一定锁定期为代价,换取在公开市场前的入场机会。一般来说,Pre-IPO价格会低于IPO发行价,为投资者留出一定的安全垫。

但同仁堂医养的情况恰恰相反,Pre-IPO轮的入股成本约7.43港元/股,而最终的IPO发行价仅为5.50港元/股,Pre-IPO投资者不仅没有享受折让,反而比IPO价格更高。

按8月18日收盘价2.665港元/股的股价计算,Pre-IPO投资者每股浮亏约64%。按照其合计持有的5720.85万股股票计算,已经浮亏约2.7亿港元。

值得关注的是,这批Pre-IPO投资者中,同仁堂养老基金、同清基金、同康基金、同仁堂医疗基金管理等机构与同仁堂体系存在关联关系。

换言之,在上市前的最后一轮融资中,“自己人”以高价入股,既是对公司估值的背书,但这也意味着如今浮亏最深的,恰恰是同仁堂体系内部资金。

基石投资者同样未能幸免。在IPO时,航空港科技资本、Aurora SF、CICCFT三家机构以5.50港元/股发行价合计认购5382.85万股,认购总成本约2.96亿港元。按当前股价计算,市值仅约1.43亿港元,浮亏约1.53亿港元。

值得一提的是,基石投资者Aurora SF背后的实际出资方海口澜鑫,有4名有限合伙人——詹永清、杨军元、林海、陈京渝,同时也是Pre-IPO轮同清基金的间接有限合伙人。这4人通过两个不同的投资主体,在Pre-IPO轮和基石轮中双重被套。

而通过公开发售中签买入的散户,则是从一开始就身处亏损之中。对于大部分参与打新的投资者来说,中签成了被套的起点。

比投资者浮亏更值得关注的,是即将到来的解禁压力。

在同仁堂医养,2027年2月6日,基石投资者率先解禁;2027年7月6日,Pre-IPO投资者和控股股东解禁。届时,两轮加起来将有超64%港股股本解禁。

随着大规模股票解禁,投资者是选择继续持有,还是割肉离场,都会进一步影响同仁堂医养的股价。

总体来看,当品牌光环褪去、业绩真相浮现,三波投资者已用真金白银为同仁堂医养的溢价买了单。同仁堂的招牌依然金光闪闪,但招牌之下,这门生意到底有多少想象空间,市场已经给出了自己的答案。

注:文/于莹,文章来源:子弹财经,本文为作者独立观点,不代表亿邦动力立场。

文章来源:子弹财经

广告
微信
朋友圈

FAQ回顾

同仁堂医养是什么公司?

同仁堂医养是同仁堂集团旗下聚焦中医医疗服务的附属公司,2015年成立,定位“医”“养”结合,提供涵盖药物与非药物疗法的现代化中医诊疗服务,按2025年门诊及住院人次计,是国内非公立中医院医疗服务行业最大的中医院集团。

同仁堂医养上市后股价表现怎么样?

同仁堂医养2026年7月在港交所上市,发行价为5.5港元/股,上市首日即暴跌39.09%,截至2026年8月18日收盘价为2.665港元/股,较发行价下跌超51%,上市仅1个月股价腰斩,中签投资者从上市首日即被套牢。

中医医疗服务行业为什么难以规模化扩张?

中医诊疗采用高度个性化的“一人一方”模式,难以像西医一样标准化复制;行业高度依赖知名医师,名医资源稀缺、培养周期长、流动性强,加之中医学术流派和地域诊疗差异大,因此天然难以公司化、连锁化扩张,行业集中度极低。

同仁堂医养存在哪些核心经营隐患?

同仁堂医养核心品牌“同仁堂”来自集团授权,自身不拥有商标所有权,若授权条款变更或集团品牌策略调整,品牌根基可能松动;同时“同仁堂”品牌存在授权乱象,品牌信用正在被透支,公司尚未建立品牌之外的核心竞争壁垒。

这么好看,分享一下?

朋友圈 分享

APP内打开

赞 +1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0